Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitorErik Maquoi, Nor Eddine Sounni, Laetitia Devy, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 21, 2010
Soluble forms of VEGF receptor-1 and -2 promote vascular maturation via mural cell recruitmentSophie Lorquet, Sarah Berndt, Silvia Blacher, et al.
Phytochemical Analysis : PCA|January 24, 2014
An easy, convenient cell and tissue extraction protocol for nuclear magnetic resonance metabolomicsNicolas Matheus, Sylvain Hansen, Eric Rozet, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 14, 2003
Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1H Roger Lijnen, Erik Maquoi, Pierre Morange, et al.
Molecules (Basel, Switzerland)|February 11, 2023
Bioactive Clerodane Diterpenoids from the Leaves of Casearia coriacea VentAllison Ledoux, Carla Hamann, Olivier Bonnet, et al.
Frontiers in Pharmacology|July 24, 2012
New and paradoxical roles of matrix metalloproteinases in the tumor microenvironmentAgnès Noël, Ana Gutiérrez-Fernández, Nor Eddine Sounni, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 22, 2010
Membrane type 1 matrix metalloproteinase detection in tumors, using the iodinated endogenous [123I]-tissue inhibitor 2 of metalloproteinases as imaging agentMagali Van Steenkiste, Ruth Oltenfreiter, Francis Frankenne, et al.
The Journal of Biological Chemistry|January 20, 2004
Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinasesNor Eddine Sounni, Christian Roghi, Vincent Chabottaux, et al.
Advanced Healthcare Materials|November 23, 2023
Poly(N-methyl-N-vinylacetamide): A Strong Alternative to PEG for Lipid-Based Nanocarriers Delivering siRNAManon Berger, François Toussaint, Sanaa Ben Djemaa, et al.
International Journal of Pharmaceutics|June 3, 2026
Quality-by-Design (QbD) optimization of lyophilization parameters for siRNA-loaded LNPs using sequential Design of Experiments (DoE)Manon Degey, Laura Meloni, Berfin Dede, et al.
Pageof 4